Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma: An in vitro study

doi:10.3748/wjg.v10.i1.53

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3017)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series.

Item

Count

PDF

281

HTML

2304

Figures (1-7)

432

Sum=3017

Jan 1, 2004 (publication date) through Jan 22, 2025

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Jan 1, 2004; 10(1): 53-57
Published online Jan 1, 2004. doi: 10.3748/wjg.v10.i1.53

Full Size Figure Download Figure

Figure 5 Lymphocyte phenotype analysis. 1 × 10⁵ SEA-T cells were stained with BD TriTEST™ antibody CD4 FITC/CD8 PE/ CD3 PerCP, and assayed by FACS. CD3⁺90.75%, CD8⁺84.46%, CD4⁺6.29%.

Citation: Lu SY, Sui YF, Li ZS, Ye J, Dong HL, Qu P, Zhang XM, Wang WY, Li YS. Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma: An in vitro study. World J Gastroenterol 2004; 10(1): 53-57
URL: https://www.wjgnet.com/1007-9327/full/v10/i1/53.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i1.53